“Clustering” people with amyotrophic lateral sclerosis (ALS) based on biological data could be useful for identifying those most likely to have slower or faster progressing disease, a new study shows. The findings were presented in a talk, “Fast Progression in Amyotrophic Lateral Sclerosis: Pathways and Biomarkers…
AAN 2022
The 2022 Annual Meeting for the American Academy of Neurology is April 2-7 in-person in Seattle and April 24-26 in a virtual format. ALS News Today is providing coverage from the meeting. Stay tuned to this page for all the latest news.
Researchers at the University of Michigan are focused on establishing cause and effect relationships between environmental and occupational exposures with amyotrophic lateral sclerosis (ALS). They hope this information will shed light on the mechanisms behind the disease and identify modifiable risk factors, which may have implications in preventing ALS.
Treatment with Radicava (edaravone) for at least one year significantly reduces the risk of death in people with amyotrophic lateral sclerosis (ALS), prolonging their survival for about six months compared with those not given the therapy, an analysis of U.S. real-life data shows. “Real-world data may provide additional insight…
Synchron’s Stentrode, an innovative, implantable brain computer interface (BCI), was found safe in four amyotrophic lateral sclerosis (ALS) patients and let them communicate and perform daily online tasks by using “just their thought,” according to one-year data from a clinical trial. The results were presented as part of…
Recent Posts
- Holding the line: Why I’d keep my ALS progression exactly as it is
- MDA 2026: Keynote speaker to MDA community: ‘Your voice is powerful’
- MDA 2026: New ALS platform trial adds RT1999 to speed search for treatments
- Making ALS Advocacy My Purpose
- MDA 2026: Wildfire smoke exposure raises risks for ALS patients